Title Page

1

2

7

- 3 The association of ethnicity and oncologic outcomes for oral cavity squamous cell
- 4 carcinoma (OSCC)
- 5 Kiana Mahboubi³, Steven C. Nakoneshny², Khara Sauro^{1,2,3,4,5,6}, Samuel Roberts^{3,7}, Rob
- 6 Hart^{2,3,5}, T Wayne Matthews^{2,3,6}, Joseph Dort^{1,2,3,5,6}, Shamir P Chandarana ^{2,3,5,6}
- ¹Department of Community Health Sciences, Cumming School of Medicine, University of
- 9 Calgary, Calgary, Alberta, Canada
- ²Ohlson Research Initiative, Arnie Charbonneau Cancer Institute, Cumming School of
- 11 Medicine, University of Calgary, Calgary, Alberta, Canada
- ³Department of Surgery, Division of Otolaryngology-Head and Neck Surgery, Cumming
- 13 School of Medicine, University of Calgary, Alberta, Canada
- ⁴O'Brien Institute of Public Health, Cumming School of Medicine, University of Calgary,
- 15 Calgary, Alberta, Canada
- ⁵Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary,
- 17 Alberta, Canada

21

22

- 18 ⁶Arnie Charbonneau Cancer Institute, Cumming School of Medicine, University of
- 19 Calgary, Calgary, Alberta, Canada
- ⁷ School of Medicine and Public Health, University of Newcastle, Newcastle, Australia

Key Words: South Asian; ethnicity; betel nut; oral squamous cell carcinoma (OSCC); oral cancer; head and neck cancer

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

Abstract **Objective:** To compare oncologic outcomes of South Asian (SA) patients treated at a regional cancer centre in Canada, for oral squamous cell carcinoma (OSCC), to the general population. Methods: Adult patients who underwent primary surgical resection of OSCC +/adjuvant treatment between 2009 and 2022 (N=697) were included. SA patients were identified using a validated method and compared to non-SA patients. Baseline characteristics, including betel nut consumption, were compared, and disease-specific survival (DSS) and recurrence-free survival (RFS) were evaluated using Kaplan-Meier methods, with median follow-up time of 36.4 months [SD 31.02]. Cox proportional hazard regression models adjusted for potential confounders. A p-value < 0.05 was considered statistically significant. **Results:** SA patients (9% of cohort, n = 64) were significantly younger and had lower rates of smoking and alcohol consumption compared to non-SA patients. There were no differences in tumor characteristics or the use of adjuvant radiation. SA patients had a two-fold higher risk of recurrence and significantly worse disease-specific survival, even after adjusting for stage and high-risk features [RFS: HR 2.01(1.28 - 3.14), DSS: HR 1.79(1.12 - 2.88)]. The consumption of betel nut was not associated with outcomes. **Conclusion**: To our knowledge, this study is the first to compare the oncological outcomes of SA patients with OSCC to non-SA patients. SA patients had significantly worse outcomes, even after controlling for known predictors of recurrence and diseasespecific survival. These findings can inform personalized treatment decisions and

Introduction

Head and neck cancer is the sixth most common cancer worldwide and is the most common neoplasm in South Asia (1). Oral cavity cancers account for 30% of all head and neck cancers and 90% of these are oral squamous cell carcinomas (OSCCs) (2,3). These cancers include tumours of the floor of the mouth, anterior tongue, alveolar ridge, retromolar trigone, the hard palate, and the buccal mucosa. According to the World Health Organization, of the 267,000 newly diagnosed OSCCs worldwide, close to 40% occurred in South Asia (India, Pakistan, Bangladesh, and Sri Lanka). Furthermore, oral cancer incidence and mortality rates in South Asia are almost twice those of global rates (4).

There are a variety of factors that are known to contribute to the development of OSCCs including the consumption of tobacco and alcohol, dental trauma, and human papilloma virus (5). The predominance of OSCCs in South Asia is often attributed to the use of betel nut (6), which can be consumed in a variety of ways but is most often dried and ground into a powder and wrapped in a package known as betel quid or pan, comprised of a mixture of slaked lime, flavouring, and tobacco. Its use is influenced by social acceptability, religious beliefs, and stimulant properties. Betel quid is often stored inside the cheek for hours similar to chewing tobacco. The slaked lime, most often used in India, is particularly problematic as it causes oxidative DNA damage and local mucosal abrasion creating deeper exposure to the carcinogenic components (7).

Although there have been improvements in the quality of life of patients with OSCC, both the disease itself as well as its treatment remain morbid with a 5-year

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

overall survival rate of 50 to 60% (8). Current treatments include surgical resection, radiotherapy, chemotherapy, or a combination of these modalities. The primary treatment for early-stage (stage I and II) and advanced-stage (stage III and IV) OSCC is surgical resection of the tumor (9). Previous North American studies have looked at the differences in head and neck cancer disease outcomes according to ethnicity, showing large disparity in mortality rates among African American versus white patients in the United States (10-12). These differences have been attributed to a combination of tumour stage at time of presentation, access to healthcare, and exposure to carcinogens. Nichols et al., reported that even after controlling for tumour stage at time of presentation, African American patients had poorer outcomes, suggesting other intrinsic and extrinsic factors such as genetics and socioeconomic status influence survival in OSCC (13). Arbes et al., accounted for socioeconomic status, which resulted in elimination of the survival disadvantage observed among black patients (14). To date, however, there has been little research that compares oncological outcomes of patients of South Asian (SA) ethnicity with OSCCs compared to other ethnicities. Our regional cancer centre, based in Calgary, Alberta, Canada, treats a high volume of OSCC, in patients with diverse ethnic backgrounds. SA patients represent a significant proportion of patients treated. Given the increased incidence and mortality rates of patients with OSCC in India, the objective of this study was to characterize oncological outcomes among patients of SA ethnicity within our centre and compare these outcomes to patients with OSCC who are not of SA ethnicity.

Methods and Material

Patient Selection

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

Adult patients (age 18 or older) that underwent curative intent primary surgical resection of OSCC at a regional cancer centre were included in the cohort. The set up of this study is that of a regional cancer centre where all head and neck cancers are managed by a multidisciplinary team with expert training and extensive experience. Patient data (n=697) was prospectively collected, and included all patients treated between 2009 to 2022. Patients with recurrent OSCC, a second primary malignancy, a synchronous primary malignancy, or who did not receive surgery as a primary treatment modality were excluded (Fig 1). Variables collected included: patient demographics, risk factors (ethnicity, age, gender, smoking and alcohol status, betel nut use), pathologic data (AJCC 8th edition TNM staging (15) including presence of extranodal extension [ENE], lymphovascular invasion [LVI], perineural invasion [PNI]), and treatment (adjuvant radiation and/or chemotherapy). Patients of SA descent were identified using a multistep approach. First, a previously constructed and validated SA surname list (16) was used to assign SA ethnicity to the patient population. The validated SA surname list was then linked with the patient database to generate a SA patient list. In addition, to ensure the accuracy of the cohort of SA patients, the final study cohort was manually entered into a surname's origin website (17). This list was reviewed by two researchers with SA/middle eastern backgrounds to generate a final list of SA patients. This method has been used successfully to identify ethnic groups in other studies (18, 19). Statistical Analysis

We interrogated a prospectively collected database of all patients treated for OSCC at the Calgary regional cancer centre. Patient factors, tumor factors, treatment factors and outcomes were analyzed and compared between the SA and non-SA groups.

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

Categorical outcomes were compared between groups using chi-square and continuous outcomes were compared using Student's t-test. Primary outcomes were recurrence-free survival (RFS) and disease specific survival (DSS). RFS was defined as time from surgery to time of last follow-up or local/regional/distant recurrence, whichever came first. DSS was defined as time from surgery to time of last follow-up or death related to OSCC. Difference in RFS and DSS between patients of SA ethnicity and those of non-SA ethnicity were determined by comparing the time-to-event (Kaplan-Meier survival curves) using a log-rank test statistic. These were censored at 3 years of follow-up. Time-to-event outcomes were then adjusted for variables that potentially modified or confounded the relationship between the outcome and exposure (social habits, stage, high risk features on surgical pathology, type of adjuvant treatment) using Cox proportional hazards (PH) regression models. These variables were, in part, based on clinical relevance, having been shown in the literature to potentially modify the oncologic outcomes (20-24). Variables that had a p-value of <0.20 in the univariate model were included in the multivariable model. Stepwise selection methods were used to develop the final models. A p-value < 0.05 was considered statistically significant. Owing to the prospective and rigorous nature of the data collection, missing data was infrequently seen; when missing data was encountered, it was excluded from analysis. Betel nut consumption was not prospectively collected, but due to the published

association between consumption and carcinogenesis, a chart review was performed, and where possible, betel nut consumption was collected. A sub-analysis of only patients of SA ethnicity was performed to look for association between betel nut consumption and oncologic outcome (DSS and RFS), by comparing the time-to-event (Kaplan-Meier survival curves) of those that did and did not consume betel nut, using a log-rank test statistic. Statistical Analysis was performed using Stata, version 14 (25). The study was approved by the University of Calgary Conjoint Health Research Ethics Board. Results

Using the previously described approach for selecting SA patients, we identified 64 SA patients and 632 non-SA patients, which served as the comparison group. We were unable to classify 1 patient as either SA or non-SA (Figure 1). Of the 697 patients that were included, 9% (n=64) were of SA ethnicity. Table 1 describes the cohort by patient and tumour characteristics stratified by ethnicity. The median follow-up time was 36.4 months (SD=31.02). SA patients were significantly younger and were less likely to smoke or drink. There were no differences in tumor pathologic characteristics (T-stage, N-stage, ENE, LVI, PNI), nor in the use of adjuvant radiation between the SA and non-SA patients.

*Recurrence free survival**

Univariate Kaplan-Meier analysis revealed that patients of SA ethnicity had

Univariate Kaplan-Meier analysis revealed that patients of SA ethnicity had worse RFS [HR=2.35 (1.51–3.65)] than those of non-SA ethnicity (Figure 2A). RFS for SA patients at 3-year follow up was 52%, compared to 76% in the non-SA group (p<0.01). Pathologic characteristics were significantly associated with worsened RFS, regardless of ethnicity: advanced T- stage [HR=2.17 (1.55–3.04)], node positivity [HR=2.98 (1.99–4.45)], presence of ENE [HR=5.39 (3.57–8.14)], advanced clinical stage [HR=5.14 (2.82–9.36)], presence of LVI [HR=2.93 (2.00–4.29)], and presence of PNI [HR=1.78 (1.24–2.55)] (Figure 2A).

After adjusting for the above-mentioned covariates on multivariable analysis, SA ethnicity [HR=2.01 (1.28 - 3.14)], advanced T-stage [HR =1.46 (1.02 - 2.10)], nodal positivity [HR=2.65 (1.77 - 3.99)], and presence of ENE [HR=4.32 (2.75 - 6.78)] were all associated with worsened RFS (Table 2).

Disease-specific survival

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

On univariate Kaplan-Meier analysis, SA ethnicity was associated with worsened disease-specific survival [HR=2.14 (1.34-3.42)]. DSS for SA patients at 3-year follow up was 59%, compared to 77% in the non-SA group (p<0.01). Other negative prognostic features included: advanced T- stage [HR=2.37 (1.66–3.36)], nodal positivity [HR=3.70 (2.38–5.74)], presence of ENE [HR=8.04 (5.24–12.35], advanced clinical stage [HR = 7.67 (3.73–15.78)], presence of LVI [HR = 3.11 (2.11–4.57)], and presence of PNI [HR = 2.20 (1.53-3.18)] (Figure 2B). After adjusting for the above-mentioned covariates on multivariable analysis, SA ethnicity [HR=1.79 (1.12-2.88)], advanced T-stage [HR = 1.64 (1.10-2.43)], node positivity [HR=3.97 (2.44–6.45)], and presence of ENE [HR=16.40 (9.00–29.91)] predicted worsened DSS (Table 3). Pattern of failure in those that recurred Among the 193 patients that developed a recurrence, 86% of patients of SA ethnicity recurred either locally or regionally, compared to the 87% in the patients of non-SA ethnicity. Conversely, 14% of patients of SA ethnicity and 13% of patients of non-SA ethnicity had distant recurrence. The difference in pattern of failure was not significant. Betel nut use in SA patients Chart review of the 64 SA patients revealed that 23 used betel nut, 28 did not use betel nut, and 13 did not have betel nut use reported. Univariate analysis of just the SA patients did not predict a difference in RFS or DSS between those who used betel nut and those who did not (Figure 3). **Discussion**

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

This study demonstrated that patients of SA ethnicity had significantly worse survival outcomes and were twice as likely to recur compared to non-SA patients even after accounting for other known factors contributing to poor oncological outcomes. The SA community is one of the largest and fastest growing minority groups in Canada based on the 2021 census (26). Considering the migration patterns within the South Asian community and their correlation with the prevalence of OSCC, it's important to acknowledge the potential impact on health trends in Canada. Understanding these patterns, can help promote public health initiatives and ensure that the unique needs of the South Asian population are met, fostering a more inclusive and supportive environment. Studies conducted in Malaysia (27,28), UK (29), Australia (30), and South Africa (31) indicate that individuals of SA heritage are at higher risk of oral cancer than the non-SA population in those countries. A study in British Columbia, which has one of the highest South Asian immigrant populations in Canada, demonstrated a relative risk of developing OSCC of 1.33 and 1.66 for South Asian men and women, respectively, as compared with the non-SA population (32). Anecdotally, the senior authors at our centre, who treat high volumes of OSCC, felt that year over year, SA patients represented a disproportionately larger ethnicity group than other ethnicities, and were recurring more frequently. The decision to formally evaluate outcomes based on SA ethnicity was therefore born out of concern for a potentially at-risk population, in hopes to validate the need for a more tailored approach to treating this group of patients, as well as to build awareness and inform public health policy.

This study uniquely evaluates differences in oncological outcomes of patients of SA ethnicity affected by OSCCs compared to patients of non-SA ethnicity. This results

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

suggest that, in Canada, SA ethnicity is an independent predictor of recurrence-free and worse disease-specific survival, when compared to non-SA patients. The study is conducted within the framework of a regional cancer center, where a dedicated multidisciplinary team, possessing expert training and extensive experience, oversees the management of all head and neck cancers. This setup intentionally minimizes bias for selection for more complicated cases. Stage of diagnosis is regarded as one of the most important predictors of oral cancer survival with a significantly improved 5-year survival rate for early-stage disease (71.4%) than for late-stage disease (21.8%) (33). In this study, when comparing baseline characteristics of SA and non-SA patients. oncological parameters such as T-Stage, N-stage, ENE, LVI and PNI were similar which suggests they were not the primary drivers of differences in recurrence and worse survival in SA patients. This association was also found in multivariable analysis. The similarity in these variables between groups also infers that there are no discrepancies in access to care, which would likely lead to a delayed presentation, with more advanced disease at time of presentation. Although, the initial presenting burden of disease is an imperfect tool to estimate access to care, in a universal health care system, issues such as treatment delay, is relatively uniform across all sub-populations. Interestingly, features that are typically protective against developing OSCC such as younger age and non-smoking status were more common in SA patients. Despite this, being SA resulted in a two-fold increase in recurrence and decrease in OSCC survival. As expected, patients with advanced T stage (T3/4), nodal disease and ENE had both worsened DSS and RFS, validating that the patient cohort in this study is representative of the greater head and neck cancer population. Disease stage at time of diagnosis has

been previously identified as a causative factor in poorer oncological outcome in minority groups (34). In this study, even after controlling for disease stage, SA ethnicity remained as an independent factor in predicting survival and recurrence.

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

Several factors potentially contribute to the poorer outcomes of OSCC in SA patients. One of the major factors is thought to be the use of betel nut in the SA culture, which is commonly consumed in the form of betel guid. Although the added tobacco plays a significant role in the development of OSCCs, studies have suggested that betel products, which contain arecoline and 3-(methylnitrosamino) propionitrile, may have an independent carcinogenic effect (35) resulting in malignant transformation of oral submucosal fibrosis (OSMF). The potential for malignant transformation resulting in OSCC has been reported to be as high as 7 to 13% (36). Although the exact mechanism is not well understood, betel nut is thought to induce c-jun proto-oncogene expression in human mucosal fibroblasts (37). The fibrosis itself can result in decreased vascularity and hypoxia thus mediating mutated cell divisions (38). This study did not find any differences on either recurrence or survival among patients of SA ethnicity based on betel nut use; however, given that betel nut consumption was not consistently reported in patient charts, further investigation with larger numbers and more consistent reporting is required to verify this finding.

Pattern of recurrence describes whether a patient recurs locally, regionally, or at a distant site. Given that betel nut is often stored inside the cheek for prolonged periods of time, one would expect SA patients to recur locoregionally if betel nut use is the causative factor. In our study population, the majority of recurrences in the SA population were local/regional however, the proportion of patients that recurred

locoregionally was not significantly different between SA and non-SA patients. This suggests that regardless of the causative agent for OSCC, recurrences are more likely to manifest as local/regional rather than distant disease.

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

A strength of this study relies on the rigorous, prospective collection of data including patient related factors, tumor factors, treatment factors and oncologic outcomes. A limitation is the relatively small sample size within the SA cohort. A larger multicentre study could yield more definitive results on this issue. Given the absence of race or ethnicity information in many databases used in health research, surnames are frequently employed as a proxy when investigating healthcare patterns within ethnic populations. Despite this, a limitation arises in potentially excluding individuals of South Asian background who may have undergone name changes. However, it should be noted that in Canada, according to the 2021 census, 76% of South Asians were recent immigrants born outside of Canada (26), and therefore, the likelihood of experiencing a name change is low. This study also did not differentiate between SA immigrants and Canadian born people of SA ethnicity (first and subsequent generations) which hinders the ability to distinguish between the role of environment versus inheritance on the findings. There are important factors related to immigration status that may mediate the findings of this study, some of which include betel nut use, environmental factors and genetic factors. Although, there is no specific data on the use of betel nut in Canada, UK and Australian data shows that it is commonly used among first generation immigrants and its use is reduced in subsequent generations (39). However, in younger generations, the form of consumption is tilting towards ingestion which may result in higher rates of esophageal cancers (39). As such, a more granular study on time since

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

immigration and mode of betel nut use would be informative. In addition to environmental factors, genetics can also play a role in the poor outcomes observed in South Asian patients with OSCC. However, no specific genes have been identified as predisposing factors for OSCC in the SA population and the hereditary factors that contribute to the disease are largely unknown. While most cases of OSCC occur sporadically, certain families with a high preponderance of the disease have been found to carry oncogenes such as VAV2 and IQGAP1 with an autosomal dominance penetrance (40). Moreover, with the emergence of precision medicine, there has been a growing interest in identifying diagnostic and prognostic biomarkers for OSCC. One such biomarker is microRNA (miRNA), a large group of small single-stranded noncoding endogenous RNAs that play a role in post-transcriptional gene regulation. Upregulation of miRNAs is thought to contribute to OSCC resistance to chemoradiation and recurrence (41). Our centre is involved in banking the tumors of all consecutive OSCC patients and intends to explore the potential molecular basis of poor OSCC outcomes in the SA population.

The findings of this study reveal that patients with SA ethnicity experience significantly poorer outcomes compared to the non-SA cohort, even after accounting for other predictors of poor outcome. To gain a more comprehensive understanding of the intricate interplay between ethnicity, environmental exposure, and genetic predisposition in OSCC outcomes, further research is imperative. Such research could pave the way for personalized treatment decisions and patient counseling, as well as the formulation of public health policies that serve to assist vulnerable and at-risk populations.

Conclusion Patients of SA ethnicity had worse outcomes (higher risk of recurrence and worsened survival) than patients with non-SA ethnicity, even after controlling for other known predictors of poor outcome in OSCC. These finding can inform more individualized treatment decision making and impact public health policy when serving heterogeneous patient populations.

References

- Parkin DM, Bray F, Ferlay J, Pisani P. Global Cancer Statistics, 2002. *CA: A Cancer Journal for Clinicians*. 2005;55(2):74-108.
- 2. Moore S, Johnson N, Pierce A, Wilson D. The epidemiology of tongue cancer: a review of global incidence. *Oral Diseases*. 2008;6(2):75-84.
- Rapidis A. Head and Neck Cancer: Multimodality Management. In: Bernier J,
 editor. Multidisciplinary management of oral cavity and maxillary sinus cancers.
 New York, NY: Springer Science 1 Business Media, LLC; 2011.
- Gupta B, Ariyawardana A, Johnson NW. Oral cancer in India continues in
 epidemic proportions: evidence base and policy initiatives. *Int Dent J*. 2013
 Jan;63(1):12-25.
- 5. Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. *Oral*Oncology. 2009;45(4-5):309-316.
- 6. IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans. Vol. 37. Tobacco habits other than smoking; Betel-quid and Betel-nut chewing; and some related nitrosamines. *Food and Chemical Toxicology*.

 1986;24(8):885-886.
- 7. Chen PH, Mahmood Q, Mariottini GL. Betel quid and oral cancer: a review with emphasis on its prevalence, etiology, and carcinogenesis. *J Environ Sci Health C Environ Carcinog Ecotoxicol Rev.* 2016;34(4):249-261.
- 8. Epstein JB, Thariat J, Bensadoun RJ, et al. Oral squamous cell carcinoma: early detection and intervention. *Can J Otolaryngol Head Neck Surg*. 2011;39(4):275-281.

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

9. National Comprehensive Cancer Network. Head and neck cancers (version 3.2021). Accessed May 4, 2023. https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf 10. Yu AJ, Choi JS, Swanson MS, et al. Association of Race/Ethnicity, Stage, and Survival in Oral Cavity Squamous Cell Carcinoma: A SEER Study. OTO Open. 2019;3(4). 11. Goodwin WJ, Thomas GR, Parker DF, et al. Unequal burden of head and neck cancer in the United States. Head Neck. 2008;30:358-371. 12. Molina MA, Cheung MC, Perez EA, et al. African American and poor patients have a dramatically worse prognosis for head and neck cancer: an examination of 20,915 patients. Cancer. 2008;113:2797-2806. 13. Nichols AC, Bhattacharyya N. Racial differences in stage and survival in head and neck squamous cell carcinoma. Laryngoscope. 2007;117:770-775. 14. Arbes SJ Jr, Olshan AF, Caplan DJ, et al. Factors contributing to the poorer survival of black Americans diagnosed with oral cancer (United States). Cancer Causes Control 1999;10:513-523. 15. AJCC. AJCC Cancer Staging Manual. 8th ed. Springer; 2017. 16. Shah BR, Chiu M, Amin S, Ramani M, Sadry S, Tu JV. Surname lists to identify South Asian and Chinese ethnicity from secondary data in Ontario, Canada: a validation study. BMC Medical Research Methodology. 2010;10(1). 17. Surnames Meanings, Origins & Distribution Maps. Forebears.io. Published 2012. https://forebears.io/surnames 18. Auluck A, Hislop G, Bajdik C, Hay J, Bottorff JL, Zhang L, Rosin MP. Gender-

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

and ethnicity-specific survival trends of oral cavity and oropharyngeal cancers in British Columbia. Cancer Causes Control. 2012;23(12):1899-1909. 19. Hislop GT, Bajdik CD, Regier MD, Barroetavena MC. Ethnic differences in survival for female cancers of the breast, cervix and colorectum in British Columbia, Canada. Asian Pac J Cancer Prev. 2007;8(2):209-214. 20. Bernier J, Cooper JS, Pajak TF, et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck. 2005;27(10):843-850. 21. Cooper JS, Pajak TF, Forastiere A, et al. Precisely defining high-risk operable head and neck tumors based on RTOG #85-03 and #88-24: targets for postoperative radiochemotherapy?. *Head Neck.* 1998;20(7):588-594. 22. Ang KK, Trotti A, Brown BW, et al. Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2001;51(3):571-578. 23. Rosenthal DI, Liu L, Lee JH, et al. Importance of the treatment package time in surgery and postoperative radiation therapy for squamous carcinoma of the head and neck. Head Neck. 2002;24(2):115-126. 24. Langendijk JA, de Jong MA, Leemans CR, et al. Postoperative radiotherapy in squamous cell carcinoma of the oral cavity: the importance of the overall treatment time. Int J Radiat Oncol Biol Phys. 2003;57(3):693-700. 25. StataCorp. 2023. Stata Statistical Software: Release 18. College Station, TX: StataCorp LLC.

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

26. Government of Canada, Statistics Canada. Census Profile, 2021 Census -Canada [Country] and Canada [Country]. Statcan.gc.ca. Published 2021. Accessed February 8, 2023. https://www12.statcan.gc.ca/censusrecensement/2016/dppd/prof/details/page.cfm?Lang=E&Geo1=PR&Code1=01&Geo2=PR&Code2=01 &Data=Count&SearchText=Canada&SearchType=Begins&SearchPR=01&B1=Et hnic%20origin&TABID=1 27. Zain RB, Ikeda N, Razak IA, et al. A national epidemiological survey of oral mucosal lesions in Malaysia. Community Dentistry and Oral Epidemiology. 1997;25(5):377-383. 28. Ali TBT, Jalaliuddin RLR, Razak IA, Zain RB. Prevalence of Oral Precancerous and Cancerous Lesions in Elderly Malaysians. Asia Pacific Journal of Public Health. 1997;9(1):24-27. 29. Warnakulasuriya S. Betel nut use following migration and its consequences. Addiction Biology. 2002;7(1):127-132. 30. Petti S. Lifestyle risk factors for oral cancer. Oral Oncology. 2009;45(4-5):340-350. 31. Van Wyk CW, Stander I, Padayachee A, Grobler-Rabie AF. The betel nut chewing habit and oral squamous cell carcinoma in South African Indians. A retrospective study. South African Medical Journal 1993;83(6):425-429. 32. Rock LM, Datta M, Laronde DM, Carraro A, Korbelik J, Harrison A, Guillaud M. Conducting community oral cancer screening among South Asians in British Columbia. *J Cancer Educ*. 2012;27(2):354-358.

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

33. Carvalho AL, Nishimoto IN, Califano JA, Kowalski LP. Trends in incidence and prognosis for head and neck cancer in the United States: A site-specific analysis of the SEER database. International Journal of Cancer. 2004;114(5):806-816. 34. Shiboski CH, Schmidt BL, Jordan RCK. Racial disparity in stage at diagnosis and survival among adults with oral cancer in the US. Community Dentistry and Oral Epidemiology. 2007;35(3):233-240. 35. Senevirathna K, Pradeep R, Jayasinghe YA, et al. Carcinogenic Effects of Betel Nut and Its Metabolites: A Review of the Experimental Evidence. Clinics and Practice. 2023;13(2):326-346. 36. Phulari RGS, Dave EJ. A systematic review on the mechanisms of malignant transformation of oral submucous fibrosis. Eur J Cancer Prev. 2020;29(5):470-473. 37. Warnakulasuriya S. Betel nut use: an independent risk factor for oral cancer. BMJ. 2002;324(7341):799-800. 38. Veeravarmal V, Austin R, Siddavaram N, Thiruneelakandan S, Nassar MHM. Caspase-3 expression in normal oral epithelium, oral submucous fibrosis and oral squamous cell carcinoma. Journal of Oral and Maxillofacial Pathology. 2016;20(3):445. 39. Auluck A, Hislop G, Poh C, Zhang L, Rosin MP. Betel nut and betel guid chewing among South Asian immigrants to Western countries and its implications for oral cancer screening. Rural Remote Health. 2009;9(2):1118. 40. Huang Y, Zhao J, Mao G, et al. Identification of novel genetic variants predisposing to familial oral squamous cell carcinomas. Cell Discovery.

2019;5(1).
41. Dioguardi M, Spirito F, Sovereto D, et al. The Prognostic Role of miR-31 in Head and Neck Squamous Cell Carcinoma: Systematic Review and Meta-Analysis with Trial Sequential Analysis. *Int J Environ Res Public Health*. 2022;19(9):5334.

Tables

Table 1. Patient Demographics

Characteristic		Non-South		
	Total	Asian	South Asian	p-value
	n=696	n=632	n=64	
Gender				ns
Female	265	244	21	
Male	431	388	43	
Age				0.0194
Mean [SD]	62.4 [13.34]	62.8 [13.24]	58.0 [13.72]	
Range	23.6 - 96.3	23.6 - 96.3	25.8 - 79.3	
Smoking History				<0.0001
Never Smoked	191	153	38	
Ex-smoker	258	244	14	
Current Smoker	227	216	10	
Not Stated	21	19	2	
Betel Nut Usage				N/A
Yes	23	N/A	23	
No	28	N/A	28	
Not Stated	13	N/A	13	
Drinking History		•		<0.0001^
Never Drinker	155	121	34	
Ex-drinker	70	66	4	
Current Drinker	411	395	16	
Not Stated	60	50	10	
Pathologic T stage				ns
T0/Tis	31	29	2	
T1	234	217	17	
T2	169	149	20	
T3	83	76	7	
T4	171	153	18	
Tx	8	8	0	

Pathologic N stage				ns
NO	268	245	23	
N1	70	64	6	
N2	138	121	17	
N3	29	25	4	
Nx	186	177	14	
Pathologic Clinical Stage				ns
Stage 0	4	3	1	
Stage I	74	70	4	
Stage II	87	77	10	
Stage III	80	73	7	
Stage IV	260	232	28	
Not Stated	191	177	14	
Extracapsular Spread				ns
ECS not present	146	131	15	
ECS present	93	81	12	
N/A (eg N0 neck)	457	420	37	
Lymphvascular Invasion				ns
Absent	500	456	44	
Present	112	102	10	
Not Stated	84	74	10	
Perineural Invasion				ns
Absent	403	363	40	
Present	202	185	17	
Not Stated	91	84	7	
Treatment				ns
Surgery Alone	427	389	38	-
Surgery + Radiation	180	166	14	
Surgery + Chemoradiation	89	77	12	

[^] Wilcoxon rank-sum test; * Fisher's exact test; ns= not significant

Table 2: Cox Regression Analysis for Recurrence Free Survival

	Univariate Analysis		Multivariable Analysis	
Variable	Hazard ratio [95% CI]	p-value	Hazard ratio [95% CI]	p-value
Ethnicity, non-SA vs SA	2.35 [1.51 - 3.65]	<0.0001	2.01 [1.28 - 3.14]	0.002
Pathologic T Classification, pT0- pT2 vs pT3-pT4	2.17 [1.55 - 3.04]	<0.0001	1.46 [1.02 - 2.10]	0.04
Pathologic Node Positivity, pN0 vs pN+	4.81 [3.08 - 7.51]	<0.0001	-	-
Clinical Stage, I/II vs III/IV	5.14 [2.82 - 9.36]	<0.0001	_	_
Lymphovascular Invasion, no vs yes	2.93 [2.00 - 4.29]	<0.0001	_	-
Perineural Invasion, no vs yes	1.78 [1.24 - 2.55]	0.002	_	_
Extracapsular Spread (ref: N0)				
N+, ECS-	2.98 [1.99 - 4.45]	<0.0001	2.65 [1.77 - 3.99]	<0.0001
N+, ECS+	5.39 [3.57 - 8.14]	<0.0001	4.32 [2.75 - 6.78]	<0.0001
Treatment Modality (ref: Surgery				
Alone)				
Surgery + Radiation	2.30 [1.57 - 3.36]	<0.0001	_	_
Surgery + Chemoradiation	2.84 [1.83 - 4.34]	<0.0001	_	

Table 3: Cox Regression Analysis for Disease Specific Survival

	Univariate Analysis		Multivariable Analysis	
Variable	Hazard ratio [95% CI]	p-value	Hazard ratio [95% CI]	p-value
Ethnicity, non-SA vs SA	2.14 [1.34 - 3.42]	0.001	1.79 [1.12 - 2.88]	0.016
Pathologic T Classification, pT0- pT2 vs pT3-pT4	2.37 [1.66 - 3.36]	<0.0001	1.64 [1.10 - 2.43]	0.015
Pathologic Node Positivity, pN0 vs pN+	6.10 [3.75 - 9.92]	<0.0001	_	-
Clinical Stage, I/II vs III/IV	7.67 [3.73 - 15.78]	<0.0001	-	_
Lymphvascular Invasion, no vs yes	3.11 [2.11 - 4.57]	<0.0001	-	_
Perineural Invasion, no vs yes	2.20 [1.53 - 3.18]	<0.0001	_	_
Bone Invasion, no vs yes	1.80 [1.11 - 2.92]	0.017	_	_
Extracapsular Spread (ref: N0)				
N+, ECS-	3.70 [2.38 - 5.74]	<0.0001	3.97 [2.44 - 6.45]	<0.0001
N+, ECS+	8.04 [5.24 - 12.35]	<0.0001	16.40 [9.00 - 29.91]	<0.0001
Treatment Modality (ref: Surgery				
Alone)				
Surgery + Radiation	2.28 [1.53 - 3.41]	<0.0001	0.85 [0.53 - 1.36]	ns
Surgery + Chemoradiation	3.14 [2.00 - 4.94]	<0.0001	0.27 [0.14 - 0.53]	<0.0001
ns= not significant				